IMNM supply chain intelligence for Immunome, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Immunome, Inc. (IMNM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AYALA-PHARMACEUTICALS-INC | AYALA-PHARMACEUTICALS-INC | 80% | In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant t… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and d… |
| BMY | Bristol-Myers Squibb Company | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMYMP | Bristol-Myers Squibb Co | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: riod. No further collaboration re… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impo… |
| MYGN | Myriad Genetics, Inc. | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSE… |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise from future legislation or administrative or executive action, either in the Unite… |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| SNYNF | Sanofi | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, imp… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV | AbbVie Inc. | 85% | Reciprocal relationship from ABBV graph: Reciprocal relationship from IMNM graph: generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have gene… |
| ABBVIE-GLOBAL-ENTERPRISES-LTD | ABBVIE-GLOBAL-ENTERPRISES-LTD | 85% | generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaborati… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. … |
| BMY | Bristol-Myers Squibb Company | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| BMYMP | Bristol-Myers Squibb Co | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s … |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good c… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY grap… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or acci… |
| MYGN | Myriad Genetics, Inc. | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulator… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise… |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| SNYNF | Sanofi | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or acc… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL g… |
| AMGN | Amgen Inc. | 62% | Reciprocal relationship from AMGN graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from AMGN g… |
| AYALA-PHARMACEUTICALS-INC | AYALA-PHARMACEUTICALS-INC | 62% | nder Section 401(k) of the Internal Revenue Code, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a por… |
| BAYER-AG | BAYER-AG | 62% | in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; • participants who enroll in clinical trials may later drop out due … |
| IN-AMGEN-INC | IN-AMGEN-INC | 62% | security incident or other interruption that has, and could in the future, result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclo… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IMNM-DEBT | Debt stack $500,000 | 90% | Market cache reports total debt of $500,000. |
| IMNM-DEBT-10242 | Warrants outstanding: 10 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| IMNM-DEBT-10243 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IMNM-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 200 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 |